All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

- Iland, Harry J., Bradstock, Ken, Reynolds, John, Di Iulio, Juliana, Tiley, Campbell, Taylor, Kerry, Filshie, Robin, Seldon, Michael, Taper, John, Szer, Jeff, Moore, John, Bashford, John, Supple, Shane G., Seymour, John F., Catalano, Alberto, Collins, Marnie, Hertzberg, Mark, Browett, Peter, Grigg, Andrew, Firkin, Frank, Hugman, Amanda

Clinical-diffusion mismatch and benefit from thrombolysis 3 to 6 hours after acute stroke

- Ebinger, Martin, Iwanaga, Takeshi, Donnan, Geoffrey A., Davis, Stephen M., Prosser, Jane F., De Silva, Deidre A., Christensen, Soren, Collins, Marnie, Parsons, Mark W., Levi, Christopher R., Bladin, Christopher F., Barber, P. Alan

Pathophysiological determinants of worse stroke outcome in atrial fibrillation

- Tu, Hans T. H., Campbell, Bruce C. V., Bladin, Christopher F., Donnan, Geoffrey A., Davis, Stephen M., Christensen, Soren, Collins, Marnie, De Silva, Deidre A., Butcher, Kenneth S., Parsons, Mark W., Desmond, Patricia M., Barber, P. Alan, Levi, Christopher R.

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

- Iland, Harry J., Collins, Marnie, Hugman, Amanda, Reynolds, John, Di Iulio, Juliana, Tiley, Campbell, Taylor, Kerry, Filshie, Robin, Seldon, Michael, Taper, John, Szer, Jeff, Moore, John, Bradstock, Ken, Bashford, John, Seymour, John F., Supple, Shane G., Catalano, Alberto, Hertzberg, Mark, Browett, Peter, Grigg, Andrew, Firkin, Frank, Campbell, Lynda J.